Imperial College London
Dr Shevanthi Nayagam

DrShevanthiNayagam

Faculty of Medicine, School of Public Health

Clinical Fellow
 
 
 
//

Contact

 

s.nayagam01

 
 
//

Location

 

Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{de:2021:10.1038/s41467-021-26475-6,
author = {de, Villiers M and Nayagam, AS and Hallett, T},
doi = {10.1038/s41467-021-26475-6},
journal = {Nature Communications},
pages = {1--10},
title = {The impact of the timely birth-dose vaccine on the global elimination of hepatitis B},
url = {http://dx.doi.org/10.1038/s41467-021-26475-6},
volume = {12},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In 2016 the World Health Organization set the goal of eliminating hepatitis B globally by 2030. Horizontal transmission has been greatly reduced in most countries by scaling up coverage of the infant HBV vaccine series, and vertical transmission is therefore becoming increasingly dominant. Here we show that scaling up timely hepatitis B birth dose vaccination to 90% of new-borns in 110 low- and middle-income countries by 2030 could prevent 710,000 (580,000 to 890,000) deaths in the 2020 to 2030 birth cohorts compared to status quo, with the greatest benefits in Africa. Maintaining this could lead to elimination by 2030 in the Americas, but not before 2059 in Africa. Drops in coverage due to disruptions in 2020 may lead to 15,000 additional deaths, mostly in South-East Asia and the Western Pacific. Delays in planned scale-up could lead to an additional 580,000 deaths globally in the 2020 to 2030 birth cohorts.
AU  - de,Villiers M
AU  - Nayagam,AS
AU  - Hallett,T
DO  - 10.1038/s41467-021-26475-6
EP  - 10
PY  - 2021///
SN  - 2041-1723
SP  - 1
TI  - The impact of the timely birth-dose vaccine on the global elimination of hepatitis B
T2  - Nature Communications
UR  - http://dx.doi.org/10.1038/s41467-021-26475-6
UR  - https://www.nature.com/articles/s41467-021-26475-6
UR  - http://hdl.handle.net/10044/1/92524
VL  - 12
ER  -
Download